Assessment of Bone Health Education in US Multiple Myeloma and Solid Tumor Patients at Risk for Skeletal-Related Events

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi:10.3322/caac.2159031912902
   PubMed Web of Science ®Google Scholar
• Huang JF, Shen J, Li X, et al. Incidence of patients with bone metastases at diagnosis of solid tumors in adults: a large population-based study. Ann Transl Med. 2020;8(7):482. doi:10.21037/atm.2020.03.5532395526
   PubMed Web of Science ®Google Scholar
• Hernandez RK, Wade SW, Reich A, Pirolli M, Liede A, Lyman GH. Incidence of bone metastases in patients with solid tumors: analysis of oncology electronic medical records in the United States. BMC Cancer. 2018;18(1):44. doi:10.1186/s12885-017-3922-029306325
   PubMed Web of Science ®Google Scholar
• Suva LJ, Washam C, Nicholas RW, Griffin RJ. Bone metastasis: mechanisms and therapeutic opportunities. Nat Rev Endocrinol. 2011;7(4):208–218. doi:10.1038/nrendo.2010.22721200394
   PubMed Web of Science ®Google Scholar
• Coleman RE. Skeletal complications of malignancy. Cancer. 1997;80(8 Suppl):1588–1594.9362426
   PubMed Web of Science ®Google Scholar
• Marino S, Roodman GD. Multiple myeloma and bone: the fatal interaction. Cold Spring Harb Perspect Med. 2018;8(8):a031286. doi:10.1101/cshperspect.a03128629229668
   PubMed Web of Science ®Google Scholar
• Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350(16):1655–1664. doi:10.1056/NEJMra03083115084698
   PubMed Web of Science ®Google Scholar
• Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med. 1996;334(8):488–493. doi:10.1056/NEJM1996022233408028559201
   PubMed Web of Science ®Google Scholar
• Kim C, Bhatta S, Cyprien L, Fonseca R, Hernandez RK. Incidence of skeletal-related events among multiple myeloma patients in the United States at oncology clinics: observations from real-world data. J Bone Oncol. 2019;14:100215. doi:10.1016/j.jbo.2018.10021530666288
   PubMed Web of Science ®Google Scholar
• Oster G, Lamerato L, Glass AG, et al. Natural history of skeletal-related events in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems. Support Care Cancer. 2013;21(12):3279–3286. doi:10.1007/s00520-013-1887-323884473
   PubMed Web of Science ®Google Scholar
• Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12(20 Pt 2):6243s–6249s. doi:10.1158/1078-0432.CCR-06-093117062708
   PubMed Web of Science ®Google Scholar
• Cetin K, Christiansen CF, Jacobsen JB, Norgaard M, Sorensen HT. Bone metastasis, skeletal-related events, and mortality in lung cancer patients: a Danish population-based cohort study. Lung Cancer. 2014;86(2):247–254. doi:10.1016/j.lungcan.2014.08.02225240518
   PubMed Web of Science ®Google Scholar
• So A, Chin J, Fleshner N, Saad F. Management of skeletal-related events in patients with advanced prostate cancer and bone metastases: incorporating new agents into clinical practice. Can Urol Assoc J. 2012;6(6):465–470. doi:10.5489/cuaj.1214923282666
   PubMed Web of Science ®Google Scholar
• Norgaard M, Jensen AO, Jacobsen JB, Cetin K, Fryzek JP, Sorensen HT. Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol. 2010;184(1):162–167. doi:10.1016/j.juro.2010.03.03420483155
   PubMed Web of Science ®Google Scholar
• Weinfurt KP, Li Y, Castel LD, et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol. 2005;16(4):579–584. doi:10.1093/annonc/mdi12215734776
   PubMed Web of Science ®Google Scholar
• Weinfurt KP, Castel LD, Li Y, Timbie JW, Glendenning GA, Schulman KA. Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions. Med Care. 2004;42(2):164–175. doi:10.1097/01.mlr.0000108746.69256.4514734954
   PubMed Web of Science ®Google Scholar
• Kunikane H, Yokota I, Katakami N, et al. Prospective analysis of the association between skeletal-related events and quality of life in patients with advanced lung cancer (CSP-HOR13). Oncol Lett. 2019;17(1):1320–1326. doi:10.3892/ol.2018.968030655901
   PubMed Web of Science ®Google Scholar
• Brodowicz T, O’Byrne K, Manegold C. Bone matters in lung cancer. Ann Oncol. 2012;23(9):2215–2222. doi:10.1093/annonc/mds00922357445
   PubMed Web of Science ®Google Scholar
• McGrath LJ, Overman RA, Reams D, et al. Use of bone-modifying agents among breast cancer patients with bone metastasis: evidence from oncology practices in the US. Clin Epidemiol. 2018;10:1349–1358. doi:10.2147/CLEP.S17506330288124
   PubMed Web of Science ®Google Scholar
• Hernandez RK, Adhia A, Wade SW, et al. Prevalence of bone metastases and bone-targeting agent use among solid tumor patients in the United States. Clin Epidemiol. 2015;7:335–345. doi:10.2147/CLEP.S8549626229504
   PubMed Web of Science ®Google Scholar
• Henry D, von Moos R, Body JJ, et al. Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in the United States. Curr Med Res Opin. 2019;35(3):375–381. doi:10.1080/03007995.2018.155884930550358
   PubMed Web of Science ®Google Scholar
• Qian Y, Bhowmik D, Kachru N, Hernandez RK. Longitudinal patterns of bone-targeted agent use among patients with solid tumors and bone metastases in the United States. Support Care Cancer. 2017;25(6):1845–1851. doi:10.1007/s00520-017-3583-128120114
   PubMed Web of Science ®Google Scholar
• Butler AM, Cetin K, Hernandez RK, et al. Treatment dynamics of bone-targeting agents among men with bone metastases from prostate cancer in the United States. Pharmacoepidemiol Drug Saf. 2018;27(2):229–238. doi:10.1002/pds.436029316026
   PubMed Web of Science ®Google Scholar